Clinical Trial

Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant

Study acronym: SLIM-1
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The study will evaluate the safety, tolerability and drug levels of a semaglutide implant placed just under the skin for a period of 4 weeks compared to 4 weekly injections of semaglutide (Wegovy) in overweight/obese participants who are otherwise healthy..
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-08 -> 2026-12 2026-07-01
minor Completion pushed: 2026-09 -> 2027-01 2026-07-01
Trial Details
NCT Number NCT07430059
Lead Sponsor Vivani Medical, Inc
Collaborators: Avance Clinical Pty Ltd.
Conditions Obesity & Overweight
Enrollment 20 participants
Start Date 2026-07
Primary Completion 2026-12 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-30